- English (USA)
- English (UK)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Bausch + Lomb Corp (BLCO)
The Bausch + Lomb share price today is 16.61, view NYSE BLCO stock exchange data. Track the latest Bausch + Lomb share price with real-time updates on BLCO stock performance including market cap, day range, 52-week range and dividend yield. Access BLCO charts, earnings dates and analyst estimates to support your investment decisions.
16.58
-0.20(-1.16%)
Real-time Data·
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
16.56
16.84
52 wk Range
13.53
18.92
BLCO is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
16.5616.84
52 wk Range
13.5318.92
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
BLCO Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Buy
Price Target
18.63
Upside
+12.33%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
5 analysts have revised their earnings downwards for the upcoming period
Bausch + Lomb receives Investment Bank Analyst Rating Update- Investing.com
Pro
- Bausch + Lomb receives Investment Bank Analyst Rating Update
- Investing.com
Pro 
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Neutral
Technical Indicators
Sell
Moving Averages
Neutral
Analyst Ratings
5 Buy
7 Hold
1 Sell
Ratings:
13 analysts
Overall Consensus
Buy
Analysts 12-Month Price Target:
Average 18.63
(+12.33% Upside)
Bausch + Lomb Corp SWOT Analysis
Ophthalmology Leade | Bausch + Lomb, a $5.01B market cap company, dominates ophthalmology with diverse eye health products, facing spin-off uncertainties amid strong growth |
Financial Resilience | Despite mixed performance, B+L shows resilience with 11% Q4 growth and 59.68% gross profit margin. Analysts project EPS of $0.50 for FY2025 |
Market Dynamics | Explore B+L's strategic positioning in the competitive ophthalmology market, with focus on innovative Dry Eye Disease treatments and new product launches |
Future Prospects | Delve into B+L's growth strategy, aiming for 5.5-7.5% expansion in 2025. Analyst targets range from $12 to $22, reflecting varied market outlooks |
Bausch + Lomb Corp Earnings Call Summary for Q2/2026
- Q2 revenue hit $1.39B, beating $1.37B estimate with 8% constant-currency growth; adjusted EPS of $0.15 matched consensus forecasts.
- Adjusted EBITDA rose 28% to $246M with margin expanding 260bps to 17.6%; net leverage declined one full turn to 4.7x year-over-year.
- Company raised FY 2026 revenue guidance to $5.44B-$5.54B and EBITDA outlook to $1.025B-$1.075B, citing stronger business performance.
- All three segments grew: surgical up 16%, pharmaceuticals up 14%, vision care up 4%; MIEBO and XIIDRA dry-eye franchise grew 27% in H1.
- Key pipeline milestones include ELIOS MIGS laser approval expected H2 2026 and enVista Beyond IOL submission targeted by end-2026.
Last Updated: 29-07-2026, 06:56 pm
Read Full TranscriptEarnings
Latest Release
29-07-2026
EPS / Forecast
0.15 / 0.15
Revenue / Forecast
1.39B / 1.37B
Compare BLCO to Peers and Sector
Metrics to compare | BLCO | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipBLCOPeersSector | |
|---|---|---|---|---|
P/E Ratio | −34.7x | 4.4x | −0.4x | |
PEG Ratio | −0.91 | −0.58 | 0.00 | |
Price/Book | 0.9x | 1.6x | 2.6x | |
Price / LTM Sales | 1.1x | 2.3x | 3.0x | |
Upside (Analyst Target) | 9.2% | 23.4% | 54.3% | |
Fair Value Upside | Unlock | 20.0% | 8.4% | Unlock |
Bausch + Lomb Corporation operates as an eye health company in the United States, Puerto Rico, China, France, Japan, Germany, the United Kingdom, Canada, Russia, Spain, Italy, Mexico, Poland, and internationally. It operates in three segments: Vision Care, Pharmaceuticals, and Surgical. The Vision Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lenses that are indicated for therapeutic use and provide optical correction during healing. It also offers contact lens care products, eye vitamins, mineral supplements, and over-the-counter eye drops that address various conditions, such as eye allergies, conjunctivitis, dry eye, and redness relief. The Pharmaceuticals segment offers proprietary and generic pharmaceutical products for post-operative treatments, as well as for the treatment of glaucoma, eye inflammation, ocular hypertension, dry eyes, and retinal diseases. The Surgical segment provides medical device equipment, consumables, and technologies for the treatment of cataracts, corneal, vitreous, and retinal eye conditions; and intraocular lenses and delivery systems, phacoemulsification equipment, and other surgical instruments and devices for cataract surgery. The company sells its products and services through direct sales forces and independent distributors. Bausch + Lomb Corporation was founded in 1853 and is headquartered in Vaughan, Canada. Bausch + Lomb Corporation operates as a subsidiary of Bausch Health Companies Inc.
Ownership
Ownership Overview
Top Holders
FAQ
What Is the Bausch + Lomb (BLCO) Share Price Today?
The Bausch + Lomb share price today is 16.58.
What is the current Bausch + Lomb (BLCO) share price and day range?
As of 04-08-2026, the Bausch + Lomb share price is 16.58, with a previous close of 16.77. The share price has ranged from 16.56 to 16.84 today, while the 52-week range spans from 13.53 to 18.92.
What Is the Bausch + Lomb Market Cap?
As of today, Bausch + Lomb market cap is 5.99B.
What Is the Bausch + Lomb (BLCO) Share Price Target?
The average 12-month share price target for Bausch + Lomb is 18.63, with a high estimate of 23 and a low estimate of 16. 5 analysts recommend buying, while 1 suggest selling, with an overall rating of Buy and +12.33% Upside potential.
What Is Bausch + Lomb's Earnings Per Share (TTM)?
The Bausch + Lomb EPS (TTM) is -0.48.
When Is the Next Bausch + Lomb Earnings Date?
Bausch + Lomb will release its next earnings report on 04-11-2026.
From a Technical Analysis Perspective, Is BLCO a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.
What Stock Exchange Does Bausch + Lomb Trade On?
Bausch + Lomb is listed and trades on the New York Stock Exchange.
What Is the Stock Symbol for Bausch + Lomb?
The stock symbol for Bausch + Lomb is "BLCO."
How Many Times Has Bausch + Lomb Stock Split?
Bausch + Lomb has split 0 times.
How Many Employees Does Bausch + Lomb Have?
Bausch + Lomb has 13000 employees.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.